Liver targeting of interferon through pullulan conjugation

被引:59
作者
Xi, KL
Tabata, Y
Uno, K
Yoshimoto, M
Kishida, T
Sokawa, Y
Ikada, Y
机构
[1] INST PASTUER KYOTO,SAKYO KU,KYOTO 606,JAPAN
[2] KYOTO UNIV,BIOMED ENGN RES CTR,SAKYO KU,KYOTO 606,JAPAN
[3] KYOTO INST TECHNOL,DEPT BIOTECHNOL,SAKYO KU,KYOTO 606,JAPAN
关键词
interferon; pullulan conjugation; liver targeting; 2-5A synthetase;
D O I
10.1023/A:1016037225728
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Purpose. The purpose of this study was to actively target interferon (IFN) to the liver through its chemical conjugation with pullulan, a water-soluble polysaccharide with a high affinity for the liver Methods. Chemical conjugation of IFN with pullulan was achieved by a cyanuric chloride method Following intravenous injection of the conjugates to mice, their body distribution and the activity of an IFN-induced enzyme, 2',5'-oligodenylate (2-5A) synthetase in the liver and other organs, were evaluated. Results. The cyanuric chloride method enabled us to prepare an IFN-pullulan conjugate that retained approximately 7-9 % of the biological activity of IFN. Pullulan conjugation enhanced the liver accumulation of IFN and the retention period with the results being reproducible. When injected intravenously to mice, the IFN-pullulan conjugate enhanced the activity of 2-5A synthetase in the liver. The activity could be induced at IFN doses much lower than those of free IFN injection. In addition, the liver 2-5A synthetase induced by conjugate injection was retained for 3 days, whereas it was lost within the first day for the free IFN-injected mice. Conclusions. IFN-pullulan conjugation was promising for IFN targeting to the liver with efficient exertion of its antiviral activity therein.
引用
收藏
页码:1846 / 1850
页数:5
相关论文
共 15 条
[1]   CARBOHYDRATE-SPECIFIC RECEPTORS OF THE LIVER [J].
ASHWELL, G ;
HARFORD, J .
ANNUAL REVIEW OF BIOCHEMISTRY, 1982, 51 :531-554
[2]   TREATMENT OF CHRONIC HEPATITIS-C WITH RECOMBINANT INTERFERON-ALFA - A MULTICENTER RANDOMIZED, CONTROLLED TRIAL [J].
DAVIS, GL ;
BALART, LA ;
SCHIFF, ER ;
LINDSAY, K ;
BODENHEIMER, HC ;
PERRILLO, RP ;
CAREY, W ;
JACOBSON, IM ;
PAYNE, J ;
DIENSTAG, JL ;
VANTHIEL, DH ;
TAMBURRO, C ;
LEFKOWITCH, J ;
ALBRECHT, J ;
MESCHIEVITZ, C ;
ORTEGO, TJ ;
GIBAS, A .
NEW ENGLAND JOURNAL OF MEDICINE, 1989, 321 (22) :1501-1506
[3]   TARGETING OF N-(2-HYDROXYPROPYL)METHACRYLAMIDE CO-POLYMERS TO LIVER BY INCORPORATION OF GALACTOSE RESIDUES [J].
DUNCAN, R ;
KOPECEK, J ;
REJMANOVA, P ;
LLOYD, JB .
BIOCHIMICA ET BIOPHYSICA ACTA, 1983, 755 (03) :518-521
[4]  
FUJITA T, 1992, J PHARMACOL EXP THER, V263, P971
[5]   PREPARATION OF 131I-LABELLED HUMAN GROWTH HORMONE OF HIGH SPECIFIC RADIOACTIVITY [J].
GREENWOOD, FC ;
HUNTER, WM .
BIOCHEMICAL JOURNAL, 1963, 89 (01) :114-&
[6]  
Ikada Y., 1993, DRUG DELIV, V1, P75, DOI DOI 10.3109/10717549309031345
[7]  
JOHNSON HM, 1994, SCI AM, V5, P41
[8]  
KOHASE M, 1982, JAPAN MED F PUBLICAT, P299
[9]   CLINICAL PHARMACOKINETICS OF DOXORUBICIN IN HEPATOMA PATIENTS AFTER A SINGLE INTRAVENOUS-INJECTION OF FREE OR NANOPARTICLE-BOUND ANTHRACYCLINE [J].
ROLLAND, A .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1989, 54 (02) :113-121
[10]   DISPOSITION OF A POLYMERIC PRODRUG OF MITOMYCIN-C, MITOMYCIN-C-DEXTRAN CONJUGATE, IN THE PERFUSED RAT-LIVER [J].
SATO, K ;
ITAKURA, K ;
NISHIDA, K ;
TAKAKURA, Y ;
HASHIDA, M ;
SEZAKI, H .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1989, 78 (01) :11-16